Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective

References

• Cancer Research UK. CancerStats – Incidence 2008 – UK. http://info.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/generalcontent/cr_072111.pdf. Accessed January 30, 2012
   Google Scholar
• Cancer Research UK. Multiple Myeloma. UK Incidence Statistics. http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/incidence/. Accessed January 30, 2012
   Google Scholar
• National Cancer Intelligence Network. Cancer Prevalence, One, Five, and Ten-Year Data. http://www.ncin.org.uk/Prevalence/1_5_10_Year/atlas.html. Accessed January 30, 2012
   Google Scholar
• Cancer Research UK. Multiple Myeloma Survival Statistics. http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/survival/. Accessed January 30, 2012
   Google Scholar
• Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2010;CD003188.
   Google Scholar
• Corso A, Ferretti E, Lunghi M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005;104:118-125
   PubMedGoogle Scholar
• Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-92
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
   PubMed Web of Science ®Google Scholar
• Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007;6:3256-62
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665-72
   PubMed Web of Science ®Google Scholar
• Uchida R, Ashihara E, Sato K, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 2007;354:613-8
   PubMed Web of Science ®Google Scholar
• Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30
   PubMed Web of Science ®Google Scholar
• Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. ASCO Meeting Abstracts 2010;28(15 Suppl):8021
   Google Scholar
• Morgan G, Davies FE, Gregory WM, et al. Zoledronic Acid (ZOL) significantly reduces Skeletal-Related Events (SREs) versus Clodronate (CLO) in Patients (Pts) with Multiple Myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX Study. Abstract 1132O. 35th European Society of Medical Oncology (ESMO) Congress, October 8, 2010, Milan, Italy. Ann Oncol 2010;21(8 Suppl):viii350-62
   Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Optimising bone disease in myeloma; zoledronic acid plus thalidomide combinations improves survival and bone endpoints: results of the MRC Myeloma IX Trial. ASH Annual Meeting Abstracts 2010;116:311
   Google Scholar
• Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119(1):7-15
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996;88:1039-45
   PubMed Web of Science ®Google Scholar
• Hornberger J, Rickert J, Dhawan R, et al. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol 2010;85:484-91
   PubMed Web of Science ®Google Scholar
• Picot J, Cooper K, Bryant J, et al. The clinical and cost-effectiveness of bortezomib and thalidomide for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Southhampton: Southampton Health Technology Assessments Centre, 2010
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Mittmann N, Evans WK, Rocchi A, et al. Addendum to CADTH’s guidelines for the economic evaluation of health technologies: specific guidance for oncology products. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009
   Google Scholar
• Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-68
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 2003;24:682-701
   PubMedGoogle Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Royal Pharmaceutical Society of Great Britain and British Medical Association. British National Formulary No. 59. London; 2010
   Google Scholar
• Botteman MF, Meijboom M, Foley I, et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ 2011;12(6):575-88
   Google Scholar
• DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;9:545-51
   PubMed Web of Science ®Google Scholar
• Paterson A, McCloskey E, Redzepovic J, et al. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. J Int Med Res 2008;36:400-13
   Google Scholar
• Department of Health. Appendix NSRC004: NHS 2009-2010 NHS Trusts and PCTs combined reference costs schedules. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459. Accessed January 30, 2012
   Google Scholar
• Department of Health. National schedule of reference costs year: ‘2008–09’ - NHS Trusts and PCTs combined non-elective inpatient (Long stay) HRG Data. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591. 2010. Accessed January 30, 2012
   Google Scholar
• Curtis L. Unit costs of health and social care 2010. Canterbury: Personal Social Services Research Unit, University of Kent, 2010
   Google Scholar
• Medisave. 2011. http://www.medisave.co.uk/. Accessed April 4, 2011
   Google Scholar
• Pickard AS, Wilke CT, Lin HW, et al. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365-84
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal; 2008. London, UK. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed January 30, 2012
   Google Scholar
• Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2
   PubMed Web of Science ®Google Scholar
• Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 2009;15:379-85
   Web of Science ®Google Scholar
• Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9:623-30
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
   PubMed Web of Science ®Google Scholar
• Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70
   PubMed Web of Science ®Google Scholar
• Weissenfeld J, Stock S, Lungen M, et al. The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharmazie 2010;65:451-6
   PubMed Web of Science ®Google Scholar